Lindahl has advised Biosergen AB on the deal.
Biosergen has carried out an issue of 5,000,000 units to the public in Sweden, Denmark and Norway. Through the issue, the company receives SEK 50 million before the deduction of issue costs.
Each Unit consists of one share and one warrant of series TO1 (together referred to as “Units”). The subscription price is SEK 10 per Unit, corresponding to SEK 10 per share and a company valuation of SEK 231 million before the Offering. The warrants are issued free of charge. The trading on Nasdaq First North Growth Market is expected to begin on June 24, 2021.
Biosergen focuses exclusively on the development of the antifungal product BSG005. BSG005 is an innovative new antifungal for the treatment of life threatening invasive fungal disease.
Lindahl’s team consisted of Monica Lagercrantz (Picture), Jenny Strandberg, Gustav Ahlgren and Ola Svanberg.
Law Firms: Lindahl;
Clients: Biosergen AB;